Candel therapeutics receives fda fast track designation for can-2409 in non-small cell lung cancer

Fast track designation has the potential to facilitate the development and expedite the u.s. fda review of can-2409 plus valacyclovir and anti-pd1 antibodies in patients with stage iii/iv non-small cell lung cancer who are resistant to first line pd-(l)1 inhibitor therapy and who do not have molecular driver mutations fast track designation has the potential to facilitate the development and expedite the u.s. fda review of can-2409 plus valacyclovir and anti-pd1 antibodies in patients with stage iii/iv non-small cell lung cancer who are resistant to first line pd-(l)1 inhibitor therapy and who do not have molecular driver mutations
CADL Ratings Summary
CADL Quant Ranking